Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15803
Abstract: In the last years, adalimumab biosimilars have represented a commonly used alternative to the originator agent in the treatment of moderate to severe hidradenitis suppurativa. As of today, studies investigating the switch from adalimumab originator… read more here.
Keywords: adalimumab originator; switch; switching adalimumab; originator biosimilars ... See more keywords
Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Pharmacy Technology"
DOI: 10.1177/87551225241306675
Abstract: Objective: Provide real-world data on switching from adalimumab biosimilar MSB11022 to GP2017 related to persistence, adherence, and safety in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Methods: Retrospective cohort… read more here.
Keywords: adalimumab biosimilar; persistence; biosimilar msb11022; gp2017 ... See more keywords